Article

Acuity improves with TTT, study says

Mountain View, CA—Patients with wet age-related macular degeneration (AMD) who were treated with a transpupillary thermotherapy (TTT) laser protocol showed a significant clinical benefit of improved vision versus those in a sham-treated control group, according to Iridex Corp.

Mountain View, CA-Patients with wet age-related macular degeneration (AMD) who were treated with a transpupillary thermotherapy (TTT) laser protocol showed a significant clinical benefit of improved vision versus those in a sham-treated control group, according to Iridex Corp.

In a subgroup of patients with baseline acuity of 20/100 or worse, 22% of treated eyes had improved vision by one or more lines compared with none of the eyes in the untreated control group, according to the company.

At 18 months, there was a 2-line benefit compared with sham-treated eyes. TTT-treated eyes lost an average of 2 lines of acuity, while sham-treated eyes lost 4 lines.

"This compares with no vision improvement for patients in the sham-treated control group," Dr. Reichel said. "These results support a role for TTT in the treatment of a significant fraction of patients with occult wet AMD worldwide."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.